Oncology · Rectal CancerTrial Updateclinicalmid-term

ROBIN Trial to Explore RT Effects on Immune System in Rectal Cancer

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

AstraZeneca66 signalsView page

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/17/2026, 6:32:00 PM

Assessment confidence: 61% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

The ROBIN trial's exploration of the immune system's response to radiotherapy in rectal cancer could lead to significant advancements in treatment protocols. Understanding these interactions may enable pharma companies to refine their strategies and enhance their competitive positioning in the oncology market. Regulatory context from FDA (FDA AP — INQOVI (SUPPL)) supports the near-term read. Assessment grounded in 13 ranked evidence items (6 high-relevance).

Strategic Assessment

Findings may lead to new therapeutic strategies that integrate immunotherapy with radiotherapy, impacting portfolio decisions for companies involved in rectal cancer treatments. The strongest clinical anchor is The Radiation Oncology-Biology Integration Network (ROBIN) Molecular Characterization Trial (MCT) of Standard Short Course Radiotherapy for Rectal Cancer (ClinicalTrials.gov), sub-indication match (colorectal cancer); entity match (national cancer institute). In colorectal cancer, 3 regulatory and 0 competitive items passed relevance filtering for National Cancer Institute.

Competitive Pressure

The most relevant competitive pressure comes from This trial could provide insights into the immunological effects of radiotherapy, potentially influencing treatment protocols and competitive positioning in rectal cancer therapies..

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — INQOVI (SUPPL) (FDA). Entity match (oncology); Regulatory pathway relevance (nda). New insights from this trial may influence regulatory considerations for treatment combinations, potentially leading to updated guidelines or approvals for novel therapies.

Key Risks

Elevated medium regulatory exposure for National Cancer Institute could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

If the trial reveals effective combinations of immunotherapy and radiotherapy, it could open new revenue streams and enhance market share for companies involved in rectal cancer treatments.
Upside for National Cancer Institute may improve if Lidocaine enhances antitumor effects of sorafenib and GW5074 in colorectal cancer cells. (PubMed) delivers favorable follow-through.
FDA does not issue approval announcements for every approval or drug label update that occurs in oncology and hematology. Please refer to Drugs@FDA for the latest approvals and prescribing information for specific products.
Upside for National Cancer Institute may improve if Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic Cancer (ClinicalTrials.gov) delivers favorable follow-through.
Upside for National Cancer Institute may improve if Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Pancreatic Neuroendocrine Tumors (ClinicalTrials.gov) delivers favorable follow-through.

What Would Change This Assessment

This becomes more urgent if Monitor trial results and any subsequent publications that may reveal new insights into treatment combinations or patient outcomes.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — INQOVI (SUPPL)
FDAmedium relevance
Entity match (oncology); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — INQOVI (SUPPL)
FDAmedium relevance
Entity match (oncology); Regulatory pathway relevance (nda)
FDA document
View source
Oncology (Cancer)/Hematologic Malignancies Approval Notifications
FDAmedium relevance
Entity match (oncology)
FDA document
View source
Janus Kinase (JAK) inhibitors: Drug Safety Communication - FDA Requires Warnings about Increased Risk of Serious Heart-related Events, Cancer, Blood Clots, and Death
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Sunscreen: How to Help Protect Your Skin from the Sun
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

The Radiation Oncology-Biology Integration Network (ROBIN) Molecular Characterization Trial (MCT) of Standard Short Course Radiotherapy for Rectal Cancer
ClinicalTrials.govhigh relevance
Sub-indication match (colorectal cancer); Entity match (national cancer institute)
FDA document
View source
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial
ClinicalTrials.govmedium relevance
Entity match (national cancer institute)
FDA document
View source
Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer
ClinicalTrials.govmedium relevance
Entity match (national cancer institute)
FDA document
View source
Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic Cancer
ClinicalTrials.govmedium relevance
Entity match (national cancer institute)
FDA document
View source
Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Pancreatic Neuroendocrine Tumors
ClinicalTrials.govmedium relevance
Entity match (national cancer institute)
FDA document
View source

No evidence in this category.

Lidocaine enhances antitumor effects of sorafenib and GW5074 in colorectal cancer cells.
PubMedhigh relevance
Sub-indication match (colorectal cancer)
FDA document
View source
Altered crosstalk of bacterial lipopolysaccharide with immune cells in colorectal cancer compared to paired adjacent intestinal tissue.
PubMedhigh relevance
Sub-indication match (colorectal cancer)
FDA document
View source
Discovery of a novel and potent KRAS(G12V)-targeting peptide with antiproliferative activity against colorectal cancer cells.
PubMedhigh relevance
Sub-indication match (colorectal cancer)
FDA document
View source
Deep learning based on CD3 histological slides for prediction of colon cancer outcome: analysis of three international stage III colon cancer cohorts.
PubMedhigh relevance
Sub-indication match (colorectal cancer)
FDA document
View source
An orthotopic organoid-based model to study early CD8⁺ T cell dysfunction and immunotherapy response in colorectal cancer.
PubMedhigh relevance
Sub-indication match (colorectal cancer)
FDA document
View source
Significance of GSH and H(2)S regulation for cancer: an intricate interplay between diet, microbiota, metabolic reprogramming, and immune health.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
RBM15B-mediated m6A modification of FOXM1 activates the AURKA/TPX2 axis to promote epithelial-mesenchymal transition-driven endometrial cancer progression.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

National Cancer Institute
Oncology

Commercial impact

medium

If the trial reveals effective combinations of immunotherapy and radiotherapy, it could open new revenue streams and enhance market share for companies involved in rectal cancer treatments.

Regulatory impact